. . . "8"^^ . . . "8"^^ . . "NT13660" . "1"^^ . " personalize approach" . "Na z\u00E1klad\u011B \u010Dinnosti a p\u016Fsobnosti 5 komplexn\u00EDch onkologick\u00FDch center \u010CR \u0159e\u0161itel a spolu\u0159e\u0161itel\u00E9 projektu vyhodnot\u00ED \u00FA\u010Dinnost multimod\u00E1ln\u00ED terapie u nemocn\u00FDch s jatern\u00EDmi metast\u00E1zami kolorekt\u00E1ln\u00EDho karcinomu sledov\u00E1n\u00EDm parametr\u016F kvality, bezpe\u010Dnosti a v\u00FDsledk\u016F l\u00E9\u010Dby a porovnaj\u00ED je s celost\u00E1tn\u00EDmi \u00FAdaji. D\u00E1le vyhodnot\u00ED p\u0159\u00EDnos neoadjuvantn\u00ED (B)CHMT u skupiny prim\u00E1rn\u011B operabiln\u00EDch a u skupiny prim\u00E1rn\u011B neoperabiln\u00EDch, ale potencion\u00E1ln\u011B resekabiln\u00EDch nemocn\u00FDch, vyhodnot\u00ED implementaci klinick\u00E9ho standardu p\u00E9\u010De o tyto nemocn\u00E9 \u010D. KKCCS0009 a zhodnot\u00ED v\u00FDznam prediktivn\u00EDch cirkuluj\u00EDc\u00EDch biomarker\u016F v\u010Detn\u011B voln\u011B cirkuluj\u00EDc\u00ED tumor\u00F3zn\u00ED DNA (circulating DNA, plasma DNA, CNA a dal\u0161\u00ED) jako faktoru \u00FA\u010Dinnosti (B)CHMT. \u0158e\u0161itel\u00E9 projektu budou sledovat kvalitu \u017Eivota t\u011Bchto nemocn\u00FDch v pr\u016Fb\u011Bhu l\u00E9\u010Dby u jednotliv\u00FDch skupin pacient\u016F, vy\u010D\u00EDsl\u00ED n\u00E1klady na jejich l\u00E9\u010Dbu dle standardn\u00EDho postupu a mo\u017Enosti ovlivn\u011Bn\u00ED pom\u011Bru cost/benefit." . . . "Based on the practice of five Czech complex oncology centres and their data, main investigator together with co-investigator will assess effectivity of multimodal treatment approach in patients with colorectal liver metastatic disease. Data will be assessed with predominant focus on quality, safety and treatment outcomes and will be compared with national data. On top of that benefit of neo-adjuvant \u201E(B)CHMT\u201C therapy will be assessed, this treatment in groups of operable and non-operable but potentially resectable patients. Impact of the KKCCS0009 standard in these groups will be investigated as well as impact of the circulating DNA, plasma DNA, CNA as a factor of \u201E(B)CHMT\u201C effectiveness. Investigators will assess quality of life together with standard treatment expenses and will try to highlight possible influence on cost-benefit."@en . . . . "0"^^ . . . " predictive biomarkers" . . "http://www.isvav.cz/projectDetail.do?rowId=NT13660"^^ . "Liver metastases of colorectal; multimodal therapy; predictive biomarkers; personalize approach; quality of life"@en . . "2012-04-01+02:00"^^ . " multimodal therapy" . "Hodnocen\u00ED kvality multimod\u00E1ln\u00ED p\u00E9\u010De u nemocn\u00FDch s jatern\u00EDmi metast\u00E1zami kolorekt\u00E1ln\u00EDho karcinomu v r\u00E1mci komplexn\u00EDch onkologick\u00FDch center \u010CR Multicentrick\u00E1 studie" . "Quality evaluation of multimodal treatment in patients with colorectal liver metastatic disease: Mutlicentric study within Czech complex oncology centres"@en . . "Liver metastases of colorectal" . "2015-12-31+01:00"^^ . "2015-01-22+01:00"^^ . "2014-03-21+01:00"^^ . "5"^^ . .